Vestipitant

Vestipitant
Clinical data

ATC code	None
Identifiers
IUPAC name (2S)-N-{(1R)-1-[3,5-bis(trifluoromethyl) phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
CAS Number	334476-64-1^Y
PubChem CID	9832383
IUPHAR/BPS	5757
ChemSpider	8008111^N
UNII	S052TOI9BI
KEGG	D06293^N
ChEMBL	CHEMBL522987^N
Chemical and physical data
Formula	C₂₃H₂₁F₁₀N₃O
Molar mass	545.416 g/mol
3D model (Jmol)	Interactive image
SMILES FC(F)(F)c1cc(F)ccc1C2CNCCN2C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(c3)C(F)(F)F
InChI InChI=1S/C23H24F7N3O/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3/t14-,20-/m1/s1^N Key:SBBYBXSFWOLDDG-JLTOFOAXSA-N^N
^NY (what is this?)

Vestipitant (INN) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK₁ receptor. It is under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia.